Dental stem cells are stem cells present within the teeth or other oral structures. They are commonly sourced from the dental pulp, the soft area within the center of the tooth. These stem cells have many uses related to tooth regeneration and repair. They also have the potential to be used across of range of regenerative medicine applications, addressing ailments from bone injuries to heart disease and arthritis. [Read more…]
What Stem Cell Clinics Do You Trust?
On a global basis, stem cell clinics have proliferated in recent years. This article explores stem cell centers within the U.S. and worldwide. Read on to learn about this emerging area of medicine. [Read more…]
Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases
TAMPA, Fla. and CAMBRIDGE, Mass., March 11, 2026 – GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a global partnership to access Catalent’s GMP-induced pluripotent stem cells (iPSC) and Catalent’s cell therapy manufacturing expertise and capabilities to support the development and clinical manufacturing of GelMEDIX’s iPSC-derived cell therapies to treat ocular and retinal diseases. [Read more…]
Gameto Licenses Foundational Meiosis IP from Harvard to Advance Human Ovary-in-a-Dish Platform
Newly licensed intellectual property enables genetic induction of early meiosis, further strengthening Gameto’s best-in-class platform for modeling human ovarian development and disease
AUSTIN, Texas, Jan. 29, 2026 –– Gameto, a clinical-stage biotechnology company advancing cell engineering solutions for women’s health, announced that it has exclusively licensed additional intellectual property from Harvard University related to the induction of meiosis in human cells. The IP builds upon prior work conducted under Gameto’s sponsored research agreement with George Church’s laboratory at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering.
Cytonome Congratulates Sumitomo Pharma on Regulatory Approval for Regenerative Medicine Therapy for Parkinson’s disease
March 11, 2026, Lexington, MA / United States — Cytonome-ST today congratulated Sumitomo Pharma Co., Ltd. following the company’s announced receipt of regulatory approval for the world’s first iPS cell-derived regenerative medicine for the treatment of Parkinson’s disease.
https://www.sumitomo-pharma.com/news/20260306.html [Read more…]
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 202
- Next Page »